Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 29, 2021 at 07:37 am
Share
Realcan Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 17,635.71 million compared to CNY 20,018.53 million a year ago. Revenue was CNY 17,635.71 million compared to CNY 20,018.53 million a year ago. Net income was CNY 125.49 million compared to CNY 249.23 million a year ago. Basic earnings per share from continuing operations was CNY 0.083 compared to CNY 0.166 a year ago. Diluted earnings per share from continuing operations was CNY 0.083 compared to CNY 0.166 a year ago.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
REALCAN PHARMACEUTICAL GROUP CO., LTD. 
